Altimmune announces positive results from 12-week phase 1 clinical trial of alt-801 (pemvidutide) in overweight and obese volunteers

Gaithersburg, md., sept. 28, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, phase 1 trial of pemvidutide (proposed inn, formerly known as alt-801), an investigational glucagon-like peptide-1 (glp-1)/glucagon dual receptor agonist.
ALT Ratings Summary
ALT Quant Ranking